Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02817828
Recruitment Status : Completed
First Posted : June 29, 2016
Results First Posted : October 4, 2019
Last Update Posted : October 4, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
Estetra

Brief Summary:
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.

Condition or disease Intervention/treatment Phase
Contraception Drug: 15 mg E4/3 mg DRSP Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1577 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone
Study Start Date : June 2016
Actual Primary Completion Date : April 26, 2018
Actual Study Completion Date : April 26, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 15 mg E4/3 mg DRSP
15 mg E4/3 mg DRSP tablet
Drug: 15 mg E4/3 mg DRSP
15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Other Name: 15 mg estetrol and 3 mg drospirenone




Primary Outcome Measures :
  1. The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening [ Time Frame: Up to 12 months (13 cycles with 1 cycle = 28 days) ]

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation.

    At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.



Secondary Outcome Measures :
  1. The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening [ Time Frame: Up to 12 months (13 cycles with 1 cycle = 28 days) ]
    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

  2. The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years) [ Time Frame: Up to 12 months (13 cycles with 1 cycle = 28 days) ]

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation.

    At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.


  3. The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years) [ Time Frame: Up to 12 months (13 cycles with 1 cycle = 28 days) ]
    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

  4. Number of Subjects With Unscheduled Bleeding/Spotting [ Time Frame: Up to 11 months (12 cycles with 1 cycle = 28 days) ]
    Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding.

  5. Number of Unscheduled Bleeding Days Per Cycle [ Time Frame: Up to 11 months (12 cycles with 1 cycle = 28 days) ]
    Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

  6. Number of Unscheduled Spotting Days Per Cycle [ Time Frame: Up to 11 months (12 cycles with 1 cycle = 28 days) ]
    Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

  7. Number of Subjects With Absence of Scheduled Bleeding and/or Spotting [ Time Frame: Up to 11 months (12 cycles with 1 cycle = 28 days) ]
    Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

  8. Number of Scheduled Bleeding and/or Spotting Days Per Cycle [ Time Frame: Up to 11 months (12 cycles with 1 cycle = 28 days) ]
    Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

  9. Number of Subjects With Abnormal Vital Signs [ Time Frame: From screening to end of treatment (12 months) ]
    Vital signs included sitting systolic and diastolic blood pressures, and heart rate.

  10. Number of Subjects With Abnormal Laboratory Assessment Results [ Time Frame: From screening to end of treatment (12 months) ]
    Laboratory assessment included blood hematology, biochemistry, and lipids

  11. Number of Subjects With Abnormal Physical Examination Results [ Time Frame: From screening to end of treatment (12 months) ]

    Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen.

    When reporting the results of the physical examination, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.


  12. Number of Subjects With Abnormal Gynecological Examination Results [ Time Frame: From screening to end of treatment (12 months) ]

    Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia.

    When reporting the results, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.


  13. Endometrial Biopsy Histology at Screening and End of Treatment [ Time Frame: Baseline and end of treatment (up to 13 cycles with 1 cycle = 28 days) ]
    Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles.

  14. Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items) [ Time Frame: Baseline and Cycle 13 (1 cycle = 28 days) ]

    The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good.

    A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score).

    In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".


  15. Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week [ Time Frame: Baseline and Cycle 13 (1 cycle = 28 days) ]

    The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good.

    A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score).

    In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".


  16. Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ) [ Time Frame: Baseline and Cycle 13 (1 cycle = 28 days) ]

    The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases.

    Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Heterosexually active female at risk for pregnancy and requesting contraception.
  • Negative serum pregnancy test at subject enrollment.
  • Willing to use the investigational product as the primary method of contraception for 13 consecutive cycles.
  • Good physical and mental health on the basis of medical, surgical and gynecological history, physical examination, gynecological examination, clinical laboratory, and vital signs.
  • Body mass index (BMI) below or equal to (≤) 35.0 kg/m2.
  • Able to fulfill the requirements of the protocol and have indicated a willingness to participate in the study by providing written informed consent (IC).
  • Willing and able to complete the diaries and questionnaires.

Exclusion Criteria:

  • Known hypersensitivity to any of the investigational product ingredients.
  • Smoking if ≥ 35 years old, at screening.
  • Any condition associated with decrease fertility.
  • Dyslipoproteinemia requiring active treatment with antilipidemic agent.
  • Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, other) or diabetes mellitus of more than 20-year duration.
  • Arterial hypertension.
  • Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism.
  • Any condition associated with abnormal uterine/vaginal bleeding.
  • Abnormal Pap test based on current international recommendations.
  • Presence of an undiagnosed breast mass.
  • Current symptomatic gallbladder disease.
  • History of COC related cholestasis.
  • Presence or history of severe hepatic disease.
  • Presence or history of pancreatitis if associated with hypertriglyceridemia.
  • Porphyria.
  • Presence or history of hepatocellular adenoma or malignant liver tumors.
  • Renal impairment.
  • Hyperkaliemia or presence of conditions that predispose to hyperkaliemia.
  • Presence or history of hormone-related malignancy.
  • History of non-hormone-related malignancy within 5 years before screening. Subjects with a non-melanoma skin cancer are allowed in the study.
  • Use of drugs potentially triggering interactions with COCs.
  • History of alcohol or drug abuse (including laxatives) within 12 months prior to screening.
  • Any condition that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.
  • Uncontrolled thyroid disorders.
  • Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to study entry. Subjects who participated in an oral contraceptive clinical study, using FDA/EU approved active ingredients, may be enrolled 2 months (60 days) after completing the preceding study.
  • Sponsor, CRO or Investigator's site personnel directly affiliated with this study.
  • Is judged by the Investigator to be unsuitable for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02817828


Locations
Layout table for location information
Belgium
Hopital Saint-Pierre
Bruxelles, Belgium, 1000
Sponsors and Collaborators
Estetra
PRA Health Sciences
Investigators
Layout table for investigator information
Study Director: Estetra Estetra
  Study Documents (Full-Text)

Documents provided by Estetra:
Study Protocol  [PDF] February 6, 2017
Statistical Analysis Plan  [PDF] June 22, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Estetra
ClinicalTrials.gov Identifier: NCT02817828    
Other Study ID Numbers: MIT-Es0001-C301
First Posted: June 29, 2016    Key Record Dates
Results First Posted: October 4, 2019
Last Update Posted: October 4, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Estetra:
Estetrol
Additional relevant MeSH terms:
Layout table for MeSH terms
Drospirenone
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents